Eisai And Biogen Announce Lecanemab-Irmb Subcutaneous Injection Is Now Available In US As Maintenance Dosing Regimen For AD Treatment

Author: Benzinga Newsdesk | October 06, 2025 03:34pm

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more

LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months

TOKYO and CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen"))) announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIK™) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of LEQEMBI (lecanemab-irmb) intravenous (IV) treatment at 10 mg/kg every two weeks, patients may either continue IV infusions at 10 mg/kg once every four weeks or start the new weekly 360 mg subcutaneous injection using the LEQEMBI IQLIK autoinjector.

Eisai and Biogen have also launched the LEQEMBI Companion™ program, an initiative rooted in both companies' commitment to providing access to LEQEMBI and resources for people living with early Alzheimer's disease. The program aims to provide expanded resources that support patients throughout their LEQEMBI treatment journey, from initiation through maintenance therapy.

In addition to the current resources already provided (e.g., help with understanding insurance coverage and potential out-of-pocket costs and identifying financial support programs), the new LEQEMBI Companion program will now offer patients:

• Injection education through Nurse Educators either in-person or virtually to provide patients with training on injecting their maintenance dose using the LEQEMBI IQLIK (nurse educators train on the device only; patients should discuss any treatment-related questions with their doctor).
• A welcome kit that includes educational resources to help patients and care partners know what to expect, prepare for at-home injections, and more.

Designed to serve as a digital solution to help support patients and care partners along their treatment journey, the LEQEMBI Companion app was developed with Medisafe, a digital patient engagement and medication management platform. From educational information about the injection process to a tool for tracking where and when injections occur, the LEQEMBI Companion app offers resources and more all in one place. Patients can visit LEQEMBI.com/CompanionAppSignUp to get started.

To further support access to LEQEMBI for certain patients who need help paying for their medicines, Eisai's Patient Assistance Program (PAP) will provide LEQEMBI and LEQEMBI IQLIK at no cost, for eligible uninsured and underinsured patients, who meet financial need and other program criteria.

Posted In: BIIB